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Abstract 17 
The mammalian endothelium which lines all blood vessels responds to soluble factors which 18 
control vascular development and sprouting. Endothelial cells bind to vascular endothelial 19 
growth factor A via two different receptor tyrosine kinases (VEGFR1, VEGFR2) which regulate 20 
such cellular responses. The integration of VEGFR signal transduction and membrane 21 
trafficking is not well understood. Here, we used a yeast-based membrane protein screen to 22 
identify VEGFR-interacting factor(s) which modulate endothelial cell function. By screening 23 
a human endothelial cDNA library, we identified a calcium-binding protein, S100A6, which 24 
can interact with either VEGFR. We found that S100A6 binds in a calcium-dependent manner 25 
to either VEGFR1 or VEGFR2. S100A6 binding was mapped to the VEGFR2 tyrosine kinase 26 
domain. Depletion of S100A6 impacts on VEGF-A-regulated signaling through the canonical 27 
mitogen-activated protein kinase (MAPK) pathway. Furthermore, S100A6 depletion caused 28 
contrasting effects on biosynthetic VEGFR delivery to the plasma membrane. Co-distribution 29 
of S100A6 and VEGFRs on tubular profiles suggest the presence of transport carriers that 30 
facilitate VEGFR trafficking. We propose a mechanism whereby S100A6 acts as a calcium-31 
regulated switch which facilitates biosynthetic VEGFR trafficking from the TGN-to-plasma 32 
membrane. VEGFR-S100A6 interactions thus enable integration of signaling and trafficking 33 
pathways in controlling the endothelial response to VEGF-A. (197 words) 34 
 35 
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Receptor tyrosine kinases (RTKs) are integral membrane proteins and enzymes which regulate 42 
essential features of cell, organ, tissue and animal function (Lemmon et al., 2016). RTK binding to 43 
exogenous ligands enables the transmission of signals into the cell interior through activation of 44 
multiple signal transduction pathways. In spite of numerous studies on different RTKs over the 45 
past 50 yrs, we still lack an understanding of how different cells integrate RTK activation, 46 
signaling and cellular responses. This is further complicated by discovery that post-translational 47 
modifications such as phosphorylation and ubiquitination can also modulate trafficking and 48 
proteolysis. This is important as the presence of activated RTK complexes at different intracellular 49 
locations could activate different signal transduction pathways.  50 
 An archetypal RTK is a Type I membrane protein with a glycosylated, extracellular N-51 
terminus which is used to 'sense' exogenous soluble and membrane-bound ligands (Lemmon and 52 
Schlessinger, 2010). Ligand binding transmits conformational changes through the single 53 
transmembrane region to the cytoplasmic domain, which activates an ~300 residue tyrosine 54 
kinase module comprised of a N- and C-lobes around a central cleft which binds ATP and protein 55 
substrates (Endres et al., 2014; Maruyama, 2015; Tatulian, 2015). RTK-mediated tyrosine 56 
phosphorylation of multiple substrates activates multiple signal transduction pathways which 57 
control different cellular responses such as migration, survival, proliferation and differentiation. 58 
Although many RTK phospho-substrates have been identified with specific roles in different 59 
aspects of cellular physiology, there is no mechanism to adequately explain how RTK trafficking 60 
is regulated in resting and ligand-stimulated conditions to meter RTK bioavailability. 61 
 One RTK model is the vascular endothelial growth receptor (VEGFRs) comprising VEGFR1, 62 
VEGFR2 and VEGFR3 (Bates et al., 2018; Simons et al., 2016). VEGFR2 is a major pro-angiogenic 63 
switch which also contributes to tumor angiogenesis (Apte et al., 2019). VEGF-A binds to both 64 
VEGFR1 and VEGFR2 with different outcomes and physiological responses (Koch and Claesson-65 
Welsh, 2012; Simons et al., 2016; Smith et al., 2015). One of the best characterized factors which 66 
interact with VEGFR2 is phospholipase C1 (PL1), whose plasma membrane recruitment 67 
promotes PIP2 hydrolysis leading to cytosolic calcium ion flux and protein kinase C activation 68 
(Takahashi et al., 2001). VEGFR2 binds a number of adaptors such as TsAd (Matsumoto et al., 69 
2005; Sun et al., 2012), Shc, Grb2, Nck (Guo et al., 1995; Kroll and Waltenberger, 1997), Crk 70 
(Stoletov et al., 2001), Shb, Sck, SHP-1, and p66Shc (Simons et al., 2016). VEGFR2 binding to epsin 71 
(Rahman et al., 2016) and synectin (Lanahan et al., 2013; Salikhova et al., 2008) suggests that 72 
interactions with endocytic regulators facilitates VEGFR2 internalization and delivery to 73 
endosomes. However, we were still lacking a mechanism to explain how VEGFR trafficking 74 
controls receptor bioavailability for exogenous VEGF-A ligand. 75 
 In this study, we explored the idea that VEGFR interaction with novel cytosolic factor(s) 76 
facilitates integration of signaling and trafficking pathways. We employed a membrane protein-77 
based genetic screen to identify VEGFR-interacting cytosolic factors. One such protein was 78 
S100A6, a calcium-binding protein which binds both VEGFR1 and VEGFR2. Calcium-dependent 79 
S100A6 binding to VEGFR1 and VEGFR2 regulates membrane trafficking and VEGF-A-regulated 80 
signal transduction. Our model postulates a feedback circuit involving calcium-dependent 81 
protein-protein interactions which modulate VEGFR trafficking and bioavailability at the plasma 82 
membrane. 83 
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S100A6 identified as a VEGFR2-binding protein using a membrane Y2H screen 85 
There has been a lack of genetic screens using a native VEGFR membrane protein to identify new 86 
binding partners and potential regulators. To address this, we used the split ubiquitin membrane 87 
yeast two-hybrid (Y2H) system (Johnsson and Varshavsky, 1994; Stagljar et al., 1998) which 88 
enables the use of native membrane proteins as ‘baits’ to screen genome-wide libraries. In this 89 
membrane Y2H system, a split ubiquitin polypeptide and the LexA-VP16 transactivator were 90 
used to control nuclear yeast gene expression (Figure 1A). The 'bait' and 'prey' are tagged with 91 
different halves of the ubiquitin molecule, which when brought together in the cytosol, allows 92 
activation of a cytosolic ubiquitin-specific protease which cleaves the LexA-VP16 transactivator 93 
from the hybrid prey (Figure 1A). Cleaved LexA-VP16 can now translocate into the yeast nucleus, 94 
and stimulates auxotrophic gene expression to enable cell growth on defined media (Figure 1A). 95 
In this study, we fused the complete human VEGFR2 coding sequence to Cub and LexA-VP16 to 96 
form a 'bait' hybrid protein to screen for binding to interacting factors (protein X) fused to the 97 
NubG ‘prey’ hybrid protein (Figure 1B).  98 
We then assessed the expression of VEGFR2 hybrid proteins using either the ‘prey’ or ‘bait’ 99 
plasmid vectors in transformed yeast cells (Figure 1C). Yeast expression of either VEGFR2-Cub-100 
LexA-VP16 or VEGFR2-NubG revealed high molecular weight bands ~200-250 kDa 101 
corresponding to the predicted size of hybrid proteins (Figure 1C). Probing yeast cells expressing 102 
Alg5-LexA-VP16 or VEGFR2-LexA-VP16 hybrid proteins using anti-VP16 antibodies again 103 
detected bands of expected sizes (Figure 1D). A positive control PLC1-SH2 domain (known to 104 
interact with VEGFR2), with an engineered HA tag was fused to NubG, expressed in yeast cells, 105 
revealing a hybrid protein of expected size (Figure 1E). This PLC1-SH2-NubG prey construct 106 
could now be used as a positive control in subsequent yeast genetic screens.   107 
We checked for yeast reporter gene expression comparing bait VEGFR2 with positive and 108 
negative controls (Supplement Figure S1). We used the PLC1-SH2 domain that binds the 109 
phosphotyrosine epitope in the VEGFR2 cytoplasmic tail (Guo et al., 1995; Takahashi et al., 2001); 110 
(Larose et al., 1995). When fused to the Nub-G prey construct, PLC1-SH2-Nub promoted a 4-5-111 
fold increase (vs. controls) in LacZ (-galactosidase) activity (Supplement Figure S1), suggesting 112 
interaction between VEGFR2 'bait' and PLC1-SH2 'prey'. We also tested whether VEGFR2 could 113 
form homodimers by co-expressing a VEGFR2-NubG 'prey' construct. Again, there was a 5-fold 114 
increase in LacZ activity (Supplement Figure S1), indicating that VEGFR2-VEGFR2 homodimers 115 
were formed. When control yeast proteins such as Fur4, Ost1 and Alg5 were fused to NubG, LacZ 116 
expression was relatively low but higher than 'empty' prey vector (Nub-G) alone. However, when 117 
the same proteins are fused to NubI, which causes self-association with the Cub moiety on the 118 
bait protein, LacZ expression was increased 5-fold (Supplement Figure S1). 119 
 120 
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Figure 1. VEGFR2 expression and interaction analysis in a membrane yeast two-hybrid system. (A) In the 123 
split-ubiquitin system, C-terminal of ubiquitin (Cub) and N-terminal of ubiquitin (Nub) spontaneously 124 
reconstitute into a native ubiquitin fold that can be recognized by ubiquitin-specific proteases (UBPs). This 125 
UBP cleaves the artificial fusion protein to release LexA-VP16 which in turn translocates to the yeast 126 
nucleus to activate reporter gene expression. Ile>Gly substitution in Nub (Nub-G) reduces affinity for Cub, 127 
blocking spontaneous Nub-Cub re-assembly. UBP-mediated proteolysis and release of VP16 promotes 128 
transcription of auxotrophic marker genes which enable survival on histidine or adenine-deficient media. 129 
Bacterial -galactosidase (LacZ) is an additional reporter controlled by LexA-VP16 nuclear translocation. 130 
(B) Schematic of the VEGFR2 bait with the full-length human VEGFR2 fused to Cub and LexA-VP16. (C) 131 
Expression and detection of VEGFR2-Cub-LexA-VP16 and VEGFR2-NubG (compared to control Alg5-132 
LexA-VP16) in yeast by immunoblotting using anti-VEGFR2 antibodies. (D) Expression of Alg5-Cub-LexA-133 
VP16 (control) and VEGFR2-Cub-LexA-VP16 hybrid proteins in yeast detected by immunoblotting using 134 
anti-VP16 antibodies. Arrowhead indicates full-length VEGFR2 fusion protein. (E) Expression of PLC1-135 
SH2-NubG prey protein in yeast detected by immunoblotting using anti-HA tag antibody. 136 
 137 
We constructed and screened a ‘prey’ cDNA library of human endothelial proteins fused 138 
to NubG-LexA-VP16 (see Materials and Methods). From this screen, we identified a calcium-139 
binding protein S100A6 as a potential binding partner for VEGFR2. The S100A6 prey plasmid 140 
construct was isolated, re-transformed into yeast cells and compared to a range of controls under 141 
defined growth conditions (Supplement Table 1). The S100A6 prey showed yeast growth when co-142 
expressed with VEGFR2 bait (Supplement Table 1), indicating protein-protein interactions between 143 
the two molecules. LacZ activity assay showed that co-expression of VEGFR2 bait and S100A6 144 
prey caused a 5-fold rise in LacZ activity (Supplement Table 1), indicating protein-protein 145 
interactions between VEGFR2 and S100A6. Biochemical analysis of S100A6-NubG in yeast cells 146 
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revealed a fusion protein of the expected size that contained an engineered HA tag (Figure S2A) 147 
and cross-reactive with anti-human S100A6 antibodies (Figure S2B). Probing human endothelial 148 
cells with anti-S100A6 antibodies revealed a low molecular weight band of ~10 kDa (Figure S2C). 149 
 150 
S100A6 binds to the VEGFR2 cytoplasmic domain 151 
Endothelial cells express both VEGFR1 and VEGFR2, two closely related but distinct gene 152 
products with distinct functional roles (Shibuya, 2015; Simons et al., 2016; Smith et al., 2015). To 153 
investigate the association of endogenously expressed VEGFRs and S100A6, we immunoisolated 154 
detergent-solubilized complexes from endothelial cells and probed for different proteins 155 
including using the transferrin receptor as a control (Figure 2A). As expected, VEGFR2 complexes 156 
contained S100A6; surprisingly, VEGFR1 complexes also contained S100A6 (Figure 2A). 157 
Immunoisolation of S100A6 complexes from endothelial cells revealed the presence of both 158 
VEGFR1 and VEGFR2 (Figure 2A). Another membrane protein, the transferrin receptor, was 159 
absent from immunoisolated complexes of VEGFR or S100A6 (Figure 2A), indicating specificity 160 
in the interaction between S100A6 and VEGFRs.  161 
S100A6 belongs to a family of relatively small (~10 kDa) proteins which undergo calcium-162 
dependent conformational changes which modulate protein-protein interactions (Rezvanpour 163 
and Shaw, 2009; Santamaria-Kisiel et al., 2006). One likelihood is that S100A6 interacts with the 164 
VEGFR2 cytoplasmic domain (Figure 1B). To test this possibility, we expressed and purified a 165 
recombinant soluble VEGFR2 cytoplasmic domain fragment to assess binding to purified 166 
recombinant S100A6 (Figure 2B). Two potential regulatory aspects of VEGFR2-S100A6 167 
interactions are calcium ion binding to S100A6 (Donato et al., 2017; Santamaria-Kisiel et al., 2006) 168 
and VEGFR2 tyrosine autophosphorylation (Simons et al., 2016; Smith et al., 2015). Interestingly, 169 
recombinant VEGFR2 exhibits phosphorylation on residue Y1175, indicating functional tyrosine 170 
kinase activity (Figure 2B). We investigated the biochemistry of VEGFR2-S100A6 interactions: 171 
VEGFR2 cytoplasmic domain bound to S100A6 in the presence of calcium ions (Figure 2A). 172 
VEGFR2-S100A6 complex formation was blocked in the presence of EGTA with no evidence for 173 
VEGFR2 association with immobilized S100A6 (Figure 2B). We then evaluated requirement for 174 
VEGFR2 tyrosine phosphorylation in binding to S100A6: de-phosphorylated VEGFR2 still bound 175 
immobilized S100A6 in the presence of calcium ions similar to phosphorylated VEGFR2 (Figure 176 
2B). Such VEGFR2-S100A6 interactions are thus calcium-dependent but do not require VEGFR2 177 
phosphorylation.  178 
As our data suggested that the VEGFR2 cytoplasmic domain binds to S100A6 (Figure 1), we 179 
asked whether the VEGFR1 cytoplasmic domain protein could also bind to S100A6 (Figure 2B). 180 
This VEGFR1 cytoplasmic domain protein bound to immobilized S100A6 in the presence of 181 
calcium ions (Figure 2C). Again, VEGFR1-S100A6 complex formation was inhibited by the 182 
addition of EGTA (Figure 2C). To investigate this further, we used the membrane Y2H system to 183 
assess whether VEGFR1 displayed interaction with S100A6 (Supplement Table 1). Yeast cells co-184 
expressing the VEGFR1-Cub-LexA-VP16 'bait' and the S100A6-Nub-G 'prey' showed auxotrophic 185 
growth and LacZ expression (Supplement Table 1). These findings are consistent with calcium-186 
dependent VEGFR1-S100A6 complex formation. 187 
 188 
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Figure 2. VEGFR and S100A6 complexes exhibit calcium-dependence. (A) Immunoisolation of VEGFR or 190 
S100A6 complexes followed by immunoblot analysis. Whole cell lysates (WCL) were subjected to detergent 191 
lysis (see Materials and Methods) and VEGFR2, VEGFR1 and S100A6 complexes isolated before SDS-PAGE 192 
and immunoblotting (IB). Goat anti-VEGFR2, goat anti-VEGFR1 or rabbit anti-S100A6 antibodies were 193 
used to isolate VEGFR or S100A6 complexes respectively. Molecular weight markers (kDa) and respective 194 
proteins are indicated in the panel. Transferrin receptor (TfR) was used as a negative control. (B) 195 
Recombinant proteins comprising soluble VEGFR2 cytoplasmic domain or de-phosphorylated VEGFR2 196 
cytoplasmic domain was incubated with soluble GST-S100A6 or GST in the presence of 1 mM calcium ions 197 
or 1 mM EGTA. This was followed by incubation with glutathione-agarose beads, centrifugation and brief 198 
washes with buffer.  Bound proteins were analyzed on 12% SDS-PAGE together with purified 199 
phosphorylated VEGFR2 (lane 9) or de-phosphorylated VEGFR2 (lane 10). Immunoblotting was carried 200 
out using mouse anti-phosphotyrosine (pY20), rabbit anti-VEGFR2-pY1175 or sheep anti-VEGFR2 201 
cytoplasmic domain antibodies. (C) Similar experiments carried out using the soluble VEGFR1 cytoplasmic 202 
domain incubated with soluble GST-S100A6 or GST in the presence of 1 mM calcium ions or 1 mM EGTA. 203 
This was followed by incubation with glutathione-agarose beads, centrifugation and brief washes with 204 
buffer. Bound proteins were analyzed on 12% SDS-PAGE and immunoblotting using sheep anti-VEGFR1 205 
cytoplasmic domain antibodies. 206 
 207 
Biochemistry of VEGFR2-S100A6 interactions 208 
The interaction between two molecules can be described by biochemical parameters. We explored 209 
the interactions between S100A6 and VEGFR2 using different assays (Figure 3). First, surface 210 
plasmon resonance (SPR) was used to measure S100A6 binding to the VEGFR2 cytoplasmic 211 
domain in the presence of calcium ions (Figure 3A). SPR data showed that titration of S100A6 212 
displayed dose-dependent kinetics of binding to immobilized VEGFR2 in the presence of calcium 213 
ions (Figure 3A). Based on these SPR data, the VEGFR2-S100A6 dissociation constant (Kd) was 214 
calculated to be ~0.2 M. S100A6 binding to immobilized VEGFR2 was abolished in the presence 215 
of EGTA (Figure 3A).  216 
The S100A6 protein (90 residues) binding to the larger VEGFR2 cytoplasmic domain (568 217 
residues) was mapped using deletion analysis (Figure 3B). We separated the 568 VEGFR2 218 
cytoplasmic domain into the juxtamembrane (JM) region, the tyrosine kinase domain comprising 219 
the N- and C- lobes (TK-N, TK-C) including a kinase insert region, and a flexible C-terminal tail 220 
(Figure 3B). These different portions of the VEGFR2 cytoplasmic domain were fused to the 221 
maltose-binding protein (MBP), and MBP-VEGFR2 hybrid proteins were tested for binding to 222 
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GST-S100A6 (Figure 3C). S100A6 protein strongly bound to the 568 residue VEGFR2 cytoplasmic 223 
domain (Figure 3C). Deletion analysis showed that the VEGFR2 kinase domain (329 residues) 224 
bound S100A6 (Figure 3C). Neither the juxtamembrane region nor the C-terminal tail showed any 225 
significant binding to S100A6 (Figure 3C).  226 
 227 
Figure 3. Interaction of the VEGFR2 cytoplasmic domain with S100A6. (A) SPR analysis of recombinant 228 
immobilized soluble VEGFR2 cytoplasmic domain binding to S100A6 the presence of 1 mM divalent 229 
calcium ions, or 1 mM EGTA (no Ca2+). Soluble VEGFR2 cytoplasmic domain was immobilized on the chip 230 
as described in Materials and Methods. GST-S100A6 solutions of 10 μM, 5 μM, 2 μM or 1 μM in buffer 231 
supplied with 1 mM calcium ions or 1 mM EGTA was flowed over immobilized VEGFR2. The response 232 
unit (RU) was recorded using evaluation software. (B) Schematic view of the VEGFR2 protein showing the 233 
various regions. The juxtamembrane (JM), tyrosine kinase domain (KD) and C-terminal tail (CT) are 234 
indicated on the line diagram. Sequences corresponding to residues from the VEGFR2 juxtamembrane 235 
(JM), kinase domain (KD) and C-terminal tail (CT) were fused to MBP and used in binding studies. (C) 236 
Interaction of MBP-VEGFR2 proteins with S100A6. The VEGFR2 cytoplasmic domain fused to MBP (Cyto), 237 
N-proximal juxtamembrane region (JM), kinase domain alone (KD) and cytoplasmic tail (CT) were tested 238 
for their ability to bind either GST or GST-S100A6 in a pull-down assay. The upper panel shows an 239 
immunoblot for GST to detect GST-S100A6 fusion; lower panel shows the Ponceau S stain showing the 240 
MBP-VEGFR2 proteins used in the assay. Molecular weight markers are indicated.  241 
 242 
S100A6 modulates VEGFR1 and VEGFR2 trafficking, modification and turnover 243 
VEGFR1 and VEGFR2 display complex patterns of steady-state and ligand-stimulated 244 
distribution in endothelial cells (Ewan et al., 2006; Gampel et al., 2006; Lampugnani et al., 2006; 245 
Mittar et al., 2009). One possibility is that calcium-dependent S100A6 interactions with VEGFR2 246 
and/or VEGFR1 modulates trafficking and turnover. To assess this, we compared S100A6 with 247 
another S100 family member (S100A10) also expressed in endothelial cells (Bao et al., 2012), using 248 
protein knockdown using RNAi followed by analyses of VEGFR trafficking and cellular 249 
distribution (Figure 4).  250 
Depletion of S100A6 caused a significant rise in overall VEGFR2 levels but this did not affect 251 
other membrane proteins including VEGFR1 or VEGF co-receptors, the neuropilins (NRP1, 252 
NRP2) (Figure 4A). In contrast, depletion of S100A10 did not significantly affect VEGFR or control 253 
membrane protein levels (Figure 4A). Quantification showed that S100A6 depletion caused ~80% 254 
rise in total VEGFR2 levels, with little or no significant effects on membrane-bound or soluble 255 
VEGFR1 levels (Figure 4B). We used cell surface biotinylation to assess plasma membrane VEGFR 256 
pools under these conditions (Figure 4C). Increased mature plasma membrane VEGFR2 levels 257 
were detected upon S100A6 knockdown (Figure 4C). Quantification showed ~2.5-fold increase in 258 
mature plasma membrane VEGFR2 levels compared to controls (Figure 4D). Under basal or 259 
resting conditions, S100A6-depleted cells showed no significant change in cell surface membrane-260 
bound or soluble VEGFR1 compared to controls (Figure 4D). 261 
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Figure 4. S100A6 requirement for VEGFR1 and VEGFR2 trafficking. Endothelial cells were subjected to 263 
RNAi on S100 proteins and analyzed for VEGFR2 trafficking. (A) Endothelial cells subjected to control, 264 
scrambled, S100A6 or S100A10 siRNA treatments were lysed and immunoblotted for various proteins 265 
indicated. Molecular weights of markers are indicated. (B) Quantification of relative protein levels under 266 
different conditions of RNAi. Color coding indicates non-transfected (red), scrambled siRNA (blue), 267 
S100A6 knockdown (purple) and S100A10 knockdown (grey). Error bars indicate +SEM (n>3). *, p<0.05. (C) 268 
Endothelial cells subjected to control, scrambled, S100A6 or S100A10 siRNA treatments followed by cell 269 
surface biotinylation, cell lysis and purification of biotinylated proteins. Whole cell lysates and purified 270 
proteins were immunoblotted for the various proteins indicated. Molecular weights of markers are also 271 
indicated. (D) Quantification of relative protein levels under different conditions of RNAi. Color coding 272 
indicates non-transfected (red), scrambled siRNA (blue), S100A6 knockdown (purple) and S100A10 273 
knockdown (grey). Error bars indicate +SEM (n>3). ***, p<0.001. (E) Quantification of VEGF-A-regulated 274 
mature VEGFR1 trafficking to the plasma membrane using cell surface biotinylation. Endothelial cells 275 
subjected to control, scrambled or S100A6 siRNA treatments followed by VEGF-A (10 ng/ml) stimulation, 276 
followed by cell surface biotinylation, cell lysis and purification of biotinylated proteins before 277 
immunoblotting. Color coding indicates non-transfected (red), scrambled siRNA (blue) and S100A6 278 
knockdown (purple). 279 
 280 
A previous study showed that biosynthetic VEGFR1 undergoes VEGF-A-stimulated and 281 
calcium-dependent trafficking from the distal Golgi to the plasma membrane (Mittar et al., 2009). 282 
One possibility was that S100A6 is involved in this calcium-dependent Golgi-to-plasma 283 
membrane trafficking step. To test this idea, we used cell surface biotinylation of S100A6-284 
depleted cells to assess VEGFR1 plasma membrane levels in resting or VEGF-A-stimulated cells 285 
(Figure 4E). Upon VEGF-A stimulation, we detected a time-dependent, ~2.5-fold increase in 286 
plasma membrane VEGFR1 levels over a 60 min time period (Figure 4E). However, S100A6 287 
knockdown caused a complete block in VEGF-A-stimulated VEGFR trafficking to the plasma 288 
membrane (Figure 4E). Depletion of S100A6, but not S100A10, thus modulates both VEGFR1 and 289 
VEGFR2 trafficking and plasma membrane levels. 290 
 291 
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S100A6 regulates VEGFR2 bioavailability and VEGF-A-stimulated signal transduction 292 
VEGFR2 trafficking influences VEGF-A-stimulated signaling from the cell surface (Bruns et al., 293 
2010; Ewan et al., 2006; Lampugnani et al., 2006; Manickam et al., 2011; Yamada et al., 2014). Based 294 
on our findings in this study, we then asked whether S100A6 regulation of plasma membrane 295 
VEGFR2 levels regulates VEGF-A-stimulated signal transduction events (Figure 5). We monitored 296 
2 different VEGFR2 phosphotyrosine epitopes (pY1175, pY1214) which exhibit different kinetics 297 
upon VEGF-A stimulation (Fearnley et al., 2016). As expected, VEGFR2-pY1175 is rapidly 298 
generated in response to VEGF-A stimulation (Figure 5A). Upon S100A6 knockdown, VEGFR2-299 
pY1175 levels are elevated (Figure 5A), corresponding to ~5-fold magnitude increase compared to 300 
controls (Figure 5B). However, the kinetics of VEGFR2-pY1175 appearance, time to peak and 301 
decline were similar in both control and S100A6-depleted endothelial cells (Figure 5B). 302 
Interestingly, VEGFR2-pY1214 is detected under basal conditions in line with previous studies 303 
(Fearnley et al., 2016); such signaling is also substantially elevated upon S100A6 knockdown in 304 
VEGF-A-stimulated cells (Figure 5A). 305 
 306 
Figure 5. Modulation of VEGFR2 signaling by S100A6. Endothelial cells were subjected to RNA interference 307 
and analyzed by (A) immunoblotting, (B) quantification of immunoblot data. Endothelial cells subjected to 308 
control, scrambled or S100A6 siRNA treatments were stimulated with VEGF-A (10 ng/ml), lysed and 309 
immunoblotted for the VEGFR2-pY1175 epitope and relative levels quantified. The blots were also probed 310 
with anti-ERK1/2 and anti-phospho-ERK1/2 antibodies to check for canonical MAPK signaling. Blotting for 311 
tubulin was used as an additional loading control in these experiments. Error bars indicate +SEM (n>3). *, 312 
p<0.05. 313 
 314 
We also carried out confocal microscopy to ascertain subcellular VEGFR and S100A6 315 
localization (Figure 6A, 6B). Steady-state VEGFR2 distribution shows localization to the plasma 316 
membrane, endosomes and juxtanuclear Golgi region (Figure 6A). In contrast, S100A6 is widely 317 
distributed in the cytosol and nucleus, with occasional staining of tubular profiles emanating 318 
from the Golgi region (Figure 6A, short arrows). Overlay images suggests co-distribution and 319 
close proximity of VEGFR2 and S100A6 (Figure 6A, boxed). Analysis of the VEGFR1 and S100A6 320 
(Figure 6B) showed also showed co-distribution in the Golgi region (Figure 6B, long arrows). Co-321 
labeling of VEGFR1 and S100A6 elongated tubular profiles emanating from the Golgi region was 322 
also detected (Figure 6B, boxed).  323 
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Figure 6. Co-distribution of VEGFRs and S100A6. Endothelial cells were fixed and processed for wide-field 325 
deconvolution microscopy analysis (see Materials and Methods) of (A) VEGFR2, or (B) VEGFR1 vs. S100A6 326 
on fixed endothelial cells. Triple color overlay shown in extreme right-hand panel. Bar, 10 m.  Arrows 327 
and arrowheads denote co-distribution of VEGFR and S100A6 along tubular profiles. Each image shown 328 
comprises 20-35 optical sections to better visualize tubular profiles. 329 
 330 
We then evaluated the 3-D structures of the S100A6 and VEGFR2 cytoplasmic domain using 331 
in silico modelling (Figure 7). Comparison of the structures of free and calcium-bound S100A6 332 
shows relatively large movements of helix H3 (Figure 7A). In silico docking studies using the 333 
VEGFR2 tyrosine kinase domain suggests that calcium-bound S100A6 binds close to the cleft of 334 
the tyrosine kinase module (Figure 7B). It is unclear whether VEGFR tyrosine kinase activity and 335 
calcium-S100A6 binding are functionally coupled. 336 
 337 
Discussion 338 
How does a cell integrate membrane receptor bioavailability for a specific ligand? In the case of 339 
VEGF-A binding to two different membrane receptors, VEGFR1 and VEGFR2, different 340 
pathways of signaling, trafficking and turnover need to be integrated to control cellular responses 341 
such as cell migration, proliferation and tubulogenesis. Up to now, we lacked molecules that 342 
could bridge VEGFR signaling and trafficking. Herein, we now present evidence that a calcium-343 
dependent cytosolic protein, S100A6, binds both VEGFR1 and VEGFR2 to integrate signaling and 344 
trafficking pathways. Five lines of evidence support this conclusion. Firstly, a genetic screen of 345 
human endothelial proteins identified S100A6 as a binding partner for VEGFR2. Second, 346 
membrane Y2H assay shows that either VEGFR2 or VEGFR1 can interact with S100A6. This was 347 
confirmed by the detection of stable complexes of S100A6 with either VEGFR1 or VEGFR2 in 348 
endothelial cells. Third, S100A6 binds the VEGFR2 cytoplasmic domain in vitro, with sub-349 
micromolar binding affinity (Kd) and displays calcium-dependence. Furthermore, the VEGFR1 350 
cytoplasmic domain also binds to S100A6 in a calcium-dependent manner. S100A6 binding to 351 
VEGFR2 maps to the tyrosine kinase module. Fourth, S100A6 regulates VEGFR1 and VEGFR2 352 
trafficking with different functional outcomes. Whereas S100A6 depletion causes dysregulated 353 
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VEGFR2 trafficking and increased plasma membrane levels, loss of S100A6 completely blocks 354 
VEGFR1 Golgi-to-plasma membrane trafficking. Finally, S100A6 influences VEGFR2 plasma 355 
membrane bioavailability by modulating VEGF-A-regulated VEGFR2 tyrosine phosphorylation 356 
and downstream canonical MAPK signaling. 357 
 358 
Figure 7. Models of VEGFR2/S100A6 interaction and membrane trafficking. (A) Crystal structures of 359 
calcium-free (grey: PDB ID 1K9P) and calcium-bound (blue: PDB ID 1K96) forms of S100A6. There is a large 360 
movement of Helix III (brown arrow) upon binding Ca2+ (red spheres). (B) Energy minimized model of 361 
VEGFR2 kinase domain (PDB ID: 4AGD) bound to calcium-bound S100A6 (PDB ID: 1K96) using in silico 362 
docking with HADDOCK 2.2 (see Materials and Methods). The kinase domain insert between the N-363 
terminal (NTD: light blue) and C-terminal (CTD: grey) segments of the kinase domain is not resolved in 364 
VEGFR2 tyrosine kinase domain structure (PDB ID: 4AGD). The regulatory loop that contains the 365 
autophosphorylation sites Y1054 and Y1059 is shown green, with the conserved DFG motif highlighted 366 
(purple). Sunitinib (Sutent: orange) is bound to the kinase domain. The major contacts contributed by 367 
S100A6 are via the interhelical Ca2+-binding loops. (C) Regulation of TGN-to-plasma membrane trafficking 368 
of VEGFR1 and VEGFR2 requiring S100A6. Depicted are 3 parallel transport routes: a constitutive transport 369 
step accessed by VEGFR2, a calcium-dependent trafficking route from the TGN which is dependent on 370 
S100A6 binding to the cytoplasmic domains of VEGFR1 and VEGFR2 cargo for inclusion into a new class 371 
of transport carriers, and the dense-core secretory granule route. 372 
 373 
Our study supports a mechanism where at least two trafficking routes regulate VEGFR 374 
delivery from the trans-Golgi network (TGN) to the plasma membrane (Figure 7C). In higher 375 
eukaryotes, a constitutive TGN-to-plasma membrane anterograde trafficking step is utilized by 376 
a majority of soluble and membrane-bound secretory proteins (Guo et al., 2014; Pakdel and von 377 
Blume, 2018). Our findings that S100A6 depletion leading to elevated VEGFR2 levels at the 378 
plasma membrane suggests dysregulation in TGN-to-plasma membrane trafficking. One 379 
explanation is that VEGFR2 utilizes both constitutive and calcium-regulated trafficking routes to 380 
exit the TGN (Figure 7C). Newly synthesized VEGFR2 also accumulates within the Golgi 381 
(Manickam et al., 2011); it was postulated constitutive TGN-to-plasma membrane trafficking 382 
enables replenishment of the cell surface VEGFR2 pool undergoing endocytosis, recycling or 383 
degradation (Ewan et al., 2006; Jopling et al., 2011). Our studies now suggest that plasma 384 
membrane VEGFR2 bioavailability is also dependent on calcium-regulated TGN-to-plasma 385 
membrane trafficking event (Figure 7C). VEGFR2 levels are thus 'metered' by 2 parallel 386 
anterograde trafficking steps to ensure that biosynthetic VEGFR2 delivery is synchronized with 387 
endocytosis of plasma membrane VEGFR2 for delivery to endosomes.  388 
 Endothelial cells display VEGFR2 localization to Golgi, plasma membrane and endosomes 389 
(Ewan et al., 2006; Gampel et al., 2006; Manickam et al., 2011). Co-distribution of VEGFR1, 390 
VEGFR2 and S100A6 on tubular profiles emanating from a juxtanuclear Golgi region in 391 
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endothelial cells indicate transport carriers which mediate VEGFR cargo delivery to the plasma 392 
membrane. VEGFR2 Golgi trafficking shows dependence on cytosolic factors such as t-SNARE 393 
syntaxin 6 (Manickam et al., 2011), the KIF13B microtubule motor (Yamada et al., 2014) and the 394 
Myo1c actomyosin motor (Tiwari et al., 2013). However, the cytoskeletal machinery involved in 395 
this calcium-regulated TGN-to-plasma membrane trafficking step (Figure 7C) is at present ill-396 
defined. 397 
 VEGFR1 intracellular localization is complicated by a lack of clear functional roles for this 398 
RTK. Generally, VEGFR1 is thought to act as a ‘VEGF sink’ which sequesters ligand and acts as a 399 
negative regulator of angiogenesis, but also modulates some aspects of cancer cell proliferation 400 
(Autiero et al., 2003; Jones et al., 2009; Lichtenberger et al., 2010; Yang et al., 2006). Different 401 
studies suggest VEGFR1 localization to Golgi (Mittar et al., 2009) and nuclear (Lee et al., 2007; 402 
Zhang et al., 2010) compartments. However, VEGFR1 plasma membrane levels are elevated by 403 
cytosolic calcium ion flux in endothelial cells (Mittar et al., 2009) and cardiomyocytes (Yang et al., 404 
2015), suggesting that VEGFR1 can undergo calcium-dependent TGN-to-plasma membrane 405 
trafficking in different cell types. Our study now provides a mechanism to explain this 406 
phenomenon with the finding that calcium-dependent binding of S100A6 to the VEGFR1 407 
cytoplasmic domain. Depletion of S100A6 levels blocked VEGF-A-stimulated VEGFR1 delivery 408 
to the plasma membrane, consistent with VEGFR1 cargo sequestration into calcium-regulated 409 
TGN-to-plasma membrane transport carriers (Figure 7C). Interestingly, the VEGFR1 Golgi pool 410 
shows partial co-distribution with TGN46, a standard marker for the human TGN (Mittar et al., 411 
2009). One explanation is that the mammalian TGN is more extensive than currently postulated, 412 
with steady-state VEGFR1 residence within a TGN-like subcompartment. From this location 413 
VEGFR1 membrane cargo is delivered to the plasma membrane via this S100A6-regulated 414 
trafficking step. 415 
 How can our proposed model (Figure 7C) be reconciled with other TGN trafficking events? 416 
The TGN is a site of multiple sorting, packaging and transport events, including constitutive and 417 
regulated secretion (Guo et al., 2014). In endothelial cells, the biogenesis of electron dense 418 
cylindrical Weibel-Palade bodies (WBPs) from the TGN precedes requirement for a calcium-419 
regulated stimulus to undergo docking and fusion with the plasma membrane (McCormack et 420 
al., 2017). However, there is little or no evidence of VEGFR1 or VEGFR2 association with WBP 421 
trafficking. This then raises the question whether such a calcium-regulated trafficking event 422 
(Figure 7C) is endothelial-specific or exists in other cell types. Interestingly, there are similarities 423 
to calcium-regulated TGN dynamics in immortalized cell lines (Pakdel and von Blume, 2018; von 424 
Blume et al., 2012) and neurons (Mikhaylova et al., 2010; Mundhenk et al., 2019). The TGN 425 
resident and calcium-binding protein Cab45 is in close proximity to a calcium pump, SPCA1 426 
(Deng et al., 2018; von Blume et al., 2012), but how this is linked to constitutive or regulated 427 
protein secretion was unknown. Recent studies suggest another member of the S100 family, 428 
S100A10, is involved in Weibel-Palade body exocytosis (Chehab et al., 2017). Our studies now 429 
suggest existence of a specialized calcium-regulated trafficking route from the TGN-to-plasma 430 
membrane in higher eukaryotes. 431 
 S100A6-VEGFR interactions involves binding to the tyrosine kinase region (Figure 7B). 432 
Deletion analysis of the VEGFR2 cytoplasmic domain maps calcium-S100A6 binding to the 433 
tyrosine kinase module. In this context, de-phosphorylation of the VEGFR2 cytoplasmic domain 434 
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at Y1175 (within the carboxy-proximal tail region) does not significantly affect VEGFR2-S100A6 435 
complex formation. Interestingly, VEGFR2 undergoes tyrosine phosphorylation at 6-8 distinct 436 
epitopes, some of which are present within the tyrosine kinase domain. It remains to be 437 
determined whether other phosphotyrosines hinder or promote S100A6 recruitment, and thus 438 
influence VEGFR TGN-to-plasma membrane trafficking. Recently, it was reported that 439 
SUMOylation of the VEGFR2 cytoplasmic domain mediates Golgi targeting (Zhou et al., 2018). 440 
SUMOylation of VEGFR2-K1270 within the flexible carboxy-terminal tail (Zhou et al., 2018) is 441 
unlikely to modulate S100A6 binding to the tyrosine kinase region (residues 833-1162; Figure 7B) 442 
in this context.  443 
 Our study provides a new mechanism where newly synthesized membrane cargo trafficking 444 
to the plasma membrane is dependent on integration with signal transduction pathways. Here, 445 
activation of plasma membrane receptors which trigger rise in second messenger levels such as 446 
calcium ions causes conformational changes in S100A6 to enable binding to VEGFRs, and cargo 447 
selection for TGN-to-plasma membrane trafficking. Importantly, our findings also provide a 448 
mechanistic explanation for how trafficking and secretion of newly synthesized membrane cargo 449 
is synergized with plasma membrane signaling for replenishment of membrane receptors. In this 450 
context, there is increasing evidence that S100 protein family members e.g. S100A10, regulates 451 
biosynthetic trafficking of sodium (Okuse et al., 2002) and potassium (Girard et al., 2002) 452 
channels, and regulates Weibel-Palade body exocytosis (Chehab et al., 2017).   453 
Our proposed mechanism enables the endothelial cell to integrate plasma membrane 454 
VEGFR2 activation, downstream signal transduction with secretion of newly synthesized 455 
VEGFRs to regulate plasma membrane VEGFR bioavailability for VEGF-A. This calcium-456 
regulated mechanism acts as a feedback loop that synchronizes VEGFR2 activation with 457 
controlling arrival of both VEGFRs at the cell surface, thus enabling tight control of cellular 458 
responses to exogenous VEGF-A. One of the puzzles in understanding VEGF biology is the 459 
existence of 2 receptor tyrosine kinases (VEGFR1, VEGFR2) that bind with differing affinity to 460 
the same ligand, VEGF-A (Ewan et al., 2006; Vaisman et al., 1990). VEGFR2 plays a major role in 461 
angiogenesis but the role of VEGFR1 is less clear (Shibuya and Claesson-Welsh, 2006). VEGFR1 462 
is postulated to negatively regulate angiogenesis by acting as a 'VEGF trap'; however, VEGFR1-463 
specific ligands such as PlGF are functionally implicated in some cancers (Fischer et al., 2008). 464 
One likelihood is that calcium-stimulated VEGFR1 arrival at the cell surface (and higher affinity 465 
for VEGF-A) dictates preferential sequestration of VEGF-A, thus reducing VEGF-A 466 
bioavailability to VEGFR2. VEGFR1 could thus not only act as a ligand trap under these 467 
situations, but have a different signaling role distinct from the pro-angiogenic VEGFR2. In tumor 468 
angiogenesis, pathological levels of exogenous VEGF-A could not only promote calcium-469 
stimulated translocation of both VEGFR1 and VEGFR2 to the plasma membrane, but continue to 470 
promote pro-angiogenic signaling through VEGFR2. Future work is needed to explore this 471 
mechanism in the context of health and disease states. 472 
 473 
Materials and Methods 474 
Gene Manipulation 475 
The full-length human VEGFR2 open reading frame was amplified using PCR using pVEGFR2-476 
EGFP (Jopling et al., 2011). The PLC1-N-SH2 domain (Larose et al., 1995) was amplified by using 477 
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pGEX-2T-PLC1-N-SH2 plasmid. Full-length VEGFR2 was cloned into both the pBT3-SUC 'bait' 478 
and pPR3-N 'prey' plasmids. The PLC1-SH2 domain was cloned into pPR3-N 'prey' plasmid. 479 
Control Fur4-NubG, Ost1-NubG, Fur4-NubI, Ost1-NubI, pBT3-SUC2, pPR3-N, Alg5-NubG, Alg-480 
NubI plasmids were already provided as controls. All recombinant constructs were checked by 481 
DNA sequence analysis. Total endothelial RNA was extracted from confluent early passage 482 
endothelial cells using Trizol (Sigma-Aldrich). 1st strand cDNA was synthesized using SMART 483 
(Switching Mechanism At 5' end of the RNA Transcript) technique using a kit (Easyclone cDNA 484 
Synthesis). The ds cDNA fragments with SfiI restriction enzyme sites was directionally cloned 485 
into the pPR3-N 'prey' plasmid which will express NubG-cDNA 'prey' fusion proteins. This 486 
cDNA library was transformed into yeast strain NMY51 containing the VEGFR2 bait by the 487 
lithium acetate transformation method. The colonies grown on media lacking histidine and 488 
adenine (SD-LWHA) plate were tested for β-galactosidase activity using an X-gal filter test and 489 
further β-galactosidase activity assay. Plasmids isolated from yeast colonies expressing β-490 
galactosidase were transformed into E. coli for plasmid purification and DNA sequencing. DNA 491 
sequence analysis was carried out using software packages at the European Bioinformatics 492 
Institute (Hinxton, UK).  493 
 494 
Construction of Endothelial cDNA Library and Membrane Y2H analysis 495 
Total RNA was extracted from confluent early passage (P0-P2) endothelial cells using Trizol 496 
(Sigma-Aldrich). 1st strand cDNA was synthesized using the Easyclone cDNA library kit with 497 
SMART (Switching Mechanism At 5' end of the RNA Transcript) technique. The cDNA fragments 498 
with SfiI restriction enzyme sites were directionally cloned into the pPR3-N 'prey' plasmid which 499 
expressed these NubG-cDNA constructs as 'prey' hybrid proteins. The cDNA library were 500 
transformed into NMY51 S.cerevisiae strain containing VEGFR2 bait construct by the lithium 501 
acetate transformation. Yeast colonies which grew on media lacking histidine and adenine (SD-502 
LWHA) were picked and re-checked for β-galactosidase (LacZ) expression using the X-gal filter 503 
test. Plasmids were isolated from blue X-gal positive colonies and retransformed into the XL-1 504 
Blue E. coli strain. Positive plasmids were sequenced and re-checked by rounds of transformation, 505 
expression and verification in the yeast assay. Quantification of β-galactosidase (LacZ) expression 506 
was done by picking several yeast colonies for each interaction pair. A high throughput β-507 
galactosidase activity kit was used to evaluate expression of this marker. 508 
 509 
Pull-down assays for protein-protein interactions 510 
Bacterial cultures of 50-500 ml expressing GST, MBP or hexahistidine-tagged constructs were 511 
lysed in buffer (1% (w/v) Triton X-100, protease cocktail inhibitors,1 mM PMSF in PBS), then 512 
subjected to rapid purification by sonication before incubation with glutathione-agarose, amylose 513 
resin or nickel-agarose beads at 4℃ for 2 h. Beads were washed 3 times, and purified proteins 514 
eluted using glutathione, maltose or imidazole respectively. In binding studies, immobilized 515 
proteins were not eluted but incubated with purified test protein in non-ionic detergent buffer 516 
(150 mM NaCl, 10 mM Tris, 1% (w/v) NP-40, 1 mM Na3VO4, 10 mM NaF, 1 mM CaCl2 or 1 mM 517 
EGTA, protease cocktail inhibitor mix, 1 mM PMSF) for 2 h at 4℃. These were then briefly 518 
centrifuged and washed with lysis buffer 3 times. 2X Sample buffer containing 5% -519 
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mercaptoethanol was added, followed by boiling and SDS-PAGE. Gels were either subjected to 520 
immunoblotting using appropriate antibodies or stained using R-250 Coomassie brilliant blue. 521 
 522 
Surface plasmon resonance (SPR) 523 
Surface plasmon resonance was used to analyze protein-protein affinity. EDC (N-ethyl-N'-524 
(dimethylaminopropyl)-carbodiimide) / NHS (N-hydroxy- succinimide) was used to activate a 525 
CM5 sensor chip flow cells #1-3. Purified soluble VEGFR2 (0.2 mg/ml in 200 mM sodium acetate, 526 
pH 5.5) was injected onto flow cell 2 to generate surface densities of 4000 RU. Rabbit anti-GST 527 
antibody in 0.2 M sodium acetate buffer was injected onto flow cell #3 to generate surface 528 
densities of 19 000 RU. Flow cell 1 was used as an activated blank flow cell. Subsequently 1 M 529 
ethanolamine pH 8.5 was injected onto each flow cell to quench unreacted esters. Different 530 
concentrations of recombinant GST-S100A6 or GST in running buffer (10 mM Tris-HCl pH 7.3, 531 
150 mM NaCl, 0.005% (v/v) surfactant P20) containing 1 mM EDTA or 1 mM CaCl2 was injected 532 
for 5 min at a flow rate of 10 μl/min sequentially over the three flow cells. Association and 533 
dissociation phases were recorded for 5 min for each reaction. Every cycle was finished with two 534 
injections of 10 mM glycine pH 1.9 (20 sec) to remove non-covalently bound proteins from the 535 
chip surface. Non-specific binding was subtracted from the activated blank flow cell for every 536 
cycle. The analyses were performed on a Biacore 3000 system and the data were evaluated with 537 
BIAevaluation 3.2 software. 538 
 539 
Cell culture, protein knockdown and immunoblotting 540 
Human umbilical vein endothelial cells (HUVECs) were cultured and analyzed as previously 541 
described (Fearnley et al., 2014). For immunoprecipitation of protein complexes from HUVECs 542 
were lysed in buffer containing 1% (w/v) n-dodecyl--D-maltoside, 150 mM NaCl, 25 mM Tris 543 
pH 7.5, 1 mM Na3VO4, 10 mM NaF, 1 mM CaCl2, protease cocktail inhibitors and 1 mM PMSF. 544 
0.5-1g of purified goat anti-VEGFR2, goat anti-VEGFR1 or mouse anti-S100A6 antibodies were 545 
added to the soluble supernatant. After 16-24 h incubation, protein G-agarose beads were added 546 
for another 2 h, briefly centrifuged and washed 3 times with lysis buffer. Samples were 547 
resuspended in 2X reducing sample buffer, boiled and subjected to SDS-PAGE and 548 
immunobotting. For signaling experiments, HUVECs were starved for 2 h in media lacking 549 
growth factors but containing 0.2% (w/v) BSA. VEGF-A (10 ng/ml) was added for different times 550 
and cells lysed in 2% SDS, PBS, protease cocktail inhibitors, 1 mM PMSF. 20g of total cell lysate 551 
was subjected to SDS-PAGE and immunoblotting. Band intensities were quantified using a 552 
digital system as previously described(Fearnley et al., 2014). For cells subjected to RNAi, 553 
endothelial cells were incubated under mock-transfection conditions or incubated with 10 nM 554 
siRNA duplex as previously described (Fearnley et al., 2016; Smith et al., 2017). Cell surface 555 
biotinylation and analysis was carried out as previously described (Fearnley et al., 2016).  556 
 557 
Confocal microscopy  558 
HUVECs were grown on glass coverslips and fixed with 3% (w/v) paraformaldehyde, quenched 559 
with 50 mM ammonium chloride, washed with PBS and subjected to a 5 min permeabilization 560 
with 0.2% (w/v) TX-100. Non-specific binding sites were blocked by incubation with 0.2% 561 
BSA/PBS blocking buffer before incubation in primary antibodies such as goat anti-VEGFR1 or 562 
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goat anti-VEGFR2 in combination with mouse anti-S100A6 (1 g/ml) for 16-20 h. After extensive 563 
washes, cells were incubated with AlexaFluor 488 donkey anti-goat and AlexaFluor 594 donkey 564 
anti-mouse conjugates (1 g/ml) for 1-2 h. After washes, coverslips were inverted on a drop of 565 
mounting medium and sealed on a glass slide. Samples were viewed using a DeltaVision wide-566 
field deconvolution microscope and 0.365 m optical sections collected as previously described 567 
(Mittar et al., 2009). Each wide-field image shown is comprises a stack of 20-35 optical sections to 568 
better visualize 3-D structures such as tubules. 569 
 570 
S100A6 and VEGFR2 modeling 571 
A structural model of the VEGFR2 tyrosine kinase domain (PDB ID:1VR2) (McTigue et al., 1999) 572 
or bound to the tyrosine kinase inhibitor Sunitinib (PDB ID: 4AGD) was used to dock the human 573 
calcium-bound S100A6 (PDB ID: 1K96) and calcium-free (PDB ID: 1K9P) (Otterbein et al., 2002). 574 
Protein structures were prepared for docking using Biovia Discovery Studio Modelling 575 
Environment, Release 3.5 (Biovia Software Inc., San Diego). A model for the complex was 576 
developed using the high ambiguity-driven protein-protein docking approach, HADDOCK 577 
(Dominguez et al., 2003), for in silico docking of the individual protein structures (using the 578 
experimentally determined structures). The Naccess program (Hubbard and Thornton, 1993) was 579 
utilized to analyze the solvent-accessible residues which were defined as the active residues for 580 
the docking protocol. Default Haddock parameters were used. The resultant docked poses were 581 
analyzed using Biovia Discovery Studio 3.5 for inter-molecular interactions. Further modelling 582 
studies were carried out using HADDOCK 2.2 (van Zundert et al., 2016) and CPORT (de Vries 583 
and Bonvin, 2011).  584 
 585 
Quantification and statistical analysis 586 
We used one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test or two-way 587 
ANOVA followed by Bonferroni multiple comparison test using GraphPad Prism software (La 588 
Jolla, USA). Significant differences between control and test groups were evaluated with P values 589 
less than 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) indicated on the graphs. Error bars in 590 
histograms denote mean ±SEM. 591 
Data availability 592 
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Abbreviations for yeast minimal (SD) culture medium additives: L, Leucine; H, Histidine; A, 821 
Adenine; W, Tryptophan. All bait plasmids were co-transformed with test prey plasmids, either 822 
as empty vector carrying only NubG (pR3-N) or carrying ORFs for denoted NubG or NubI hybrid 823 
proteins. Fur4 yeast plasma membrane protein expression was used as another negative control. 824 
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Figure S1. Measurement of β-galactosidase reporter activity with different bait and prey 850 
combinations. Co-expression of VEGFR2 bait with control NubG (alone) or NubG fused to Alg5, 851 
Ost1 or Fur4 (negative controls) or NubI fused to Alg5, Ost1 or Fur4 (non-specific control). Co-852 
expression of VEGFR2-Cub bait with VEGFR2, PLC1-SH2 or S100A6 test proteins fused to 853 
NubG. LacZ activity assay representative of 3 or more independent experiments.  854 
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Figure S2. Human S100A6 expression in yeast and primary human endothelial cells. (A) Expression 863 
and detection of S100A6-NubG in yeast by immunoblotting using anti-HA antibodies. (D) Expression and 864 
detection of S100A6-NubG in yeast by immunoblotting using anti-S100A6 antibodies. (E) Expression and 865 
detection of human endothelial S100A6 and S100A6-NubG in yeast by immunoblotting using anti-S100A6 866 
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